Covishield Controversy

The Covishield controversy centers around AstraZeneca’s recent admission in a UK court that its COVID-19 vaccine, developed with the University of Oxford and sold in India as Covishield, can cause Thrombosis with Thrombocytopenia Syndrome (TTS) in rare instances. This admission surfaced during a class-action lawsuit, where claimants are seeking damages for severe injuries and fatalities allegedly caused by the vaccine. Despite the rare risk of TTS, which manifests as blood clots accompanied by a low platelet count, health professionals emphasize the vaccine’s crucial role in preventing severe COVID-19, which itself can lead to similar health complications. The situation highlights the ongoing balance between vaccine efficacy and the management of potential side effects.

Related Posts

Notify of
Inline Feedbacks
View all comments
Home Courses Plans Account